

Alexander Kautzky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2036833/publications.pdf>

Version: 2024-02-01

61
papers

1,665
citations

279701

23
h-index

330025

37
g-index

69
all docs

69
docs citations

69
times ranked

2452
citing authors

#	ARTICLE	IF	CITATIONS
1	Biological and Psychological Stress Correlates Are Linked to Glucose Metabolism, Obesity, and Gender Roles in Women. <i>Neuroendocrinology</i> , 2022, 112, 130-142.	1.2	6
2	Neonatal outcome and adaption after in utero exposure to antidepressants: A systematic review and meta-analysis. <i>Acta Psychiatrica Scandinavica</i> , 2022, 145, 6-28.	2.2	24
3	Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 114, 110480.	2.5	3
4	The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022, 272, 715-727.	1.8	14
5	Depressive symptoms as a transdiagnostic mediator of mother-to-infant bonding: Results from a psychiatric mother-baby unit. <i>Journal of Psychiatric Research</i> , 2022, 149, 37-43.	1.5	4
6	The sociodemographic and clinical phenotype of European patients with major depressive disorder undergoing first-line antidepressant treatment with NaSSAs. <i>Journal of Affective Disorders</i> , 2022, 312, 225-234.	2.0	2
7	Combining machine learning algorithms for prediction of antidepressant treatment response. <i>Acta Psychiatrica Scandinavica</i> , 2021, 143, 36-49.	2.2	31
8	Association of norepinephrine transporter methylation with in vivo NET expression and hyperactivity-related impulsivity symptoms in ADHD measured with PET. <i>Molecular Psychiatry</i> , 2021, 26, 1009-1018.	4.1	23
9	Major Depressive Disorder (MDD) and Antidepressant Medication Are Overrepresented in High-Dose Statin Treatment. <i>Frontiers in Medicine</i> , 2021, 8, 608083.	1.2	5
10	The Influence of Acute SSRI Administration on White Matter Microstructure in Patients Suffering From Major Depressive Disorder and Healthy Controls. <i>International Journal of Neuropsychopharmacology</i> , 2021, 24, 542-550.	1.0	15
11	Risk of Typical Diabetes-Associated Complications in Different Clusters of Diabetic Patients: Analysis of Nine Risk Factors. <i>Journal of Personalized Medicine</i> , 2021, 11, 328.	1.1	11
12	The Role of Relationship Status in Major Depressive Disorder - Results of the European Group for the Study of Resistant Depression. <i>Journal of Affective Disorders</i> , 2021, 286, 149-157.	2.0	4
13	Sex-related effects in major depressive disorder: Results of the European Group for the Study of Resistant Depression. <i>Depression and Anxiety</i> , 2021, 38, 896-906.	2.0	18
14	Melancholic features in major depression – a European multicenter study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 110, 110285.	2.5	17
15	Insulin as Monotherapy and in Combination with Other Glucose-Lowering Drugs Is Related to Increased Risk of Diagnosis of Pneumonia: A Longitudinal Assessment over Two Years. <i>Journal of Personalized Medicine</i> , 2021, 11, 984.	1.1	3
16	Short Term Caloric Restriction and Biofeedback Enhance Psychological Wellbeing and Reduce Overweight in Healthy Women. <i>Journal of Personalized Medicine</i> , 2021, 11, 1096.	1.1	2
17	The Choice of either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients with Major Depressive Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2021, , .	1.0	2
18	Effects of media stories featuring coping with suicidal crises on psychiatric patients: Randomized controlled trial. <i>European Psychiatry</i> , 2021, 64, 1-12.	0.1	2

#	ARTICLE	IF	CITATIONS
19	Sex-Specific Differences in Mortality of Patients with a History of Bariatric Surgery: a Nation-Wide Population-Based Study. <i>Obesity Surgery</i> , 2021, , 1.	1.1	5
20	Add-on benzodiazepine treatment in patients with major depressive disorder – results from a European cross-sectional multicenter study. <i>European Neuropsychopharmacology</i> , 2020, 41, 70-80.	0.3	14
21	Diabetes mellitus is associated with a higher risk for major depressive disorder in women than in men. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001430.	1.2	44
22	Psychopharmacological Medication Has No Influence on Vitamin Status After Bariatric Surgery in Long-term Follow-up. <i>Obesity Surgery</i> , 2020, 30, 3753-3760.	1.1	0
23	A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping. <i>Translational Psychiatry</i> , 2020, 10, 50.	2.4	33
24	Machine learning classification of ADHD and HC by multimodal serotonergic data. <i>Translational Psychiatry</i> , 2020, 10, 104.	2.4	39
25	Results of the European Group for the Study of Resistant Depression (GSRD) – basis for further research and clinical practice. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 427-448.	1.3	89
26	Serotonin Transporter Binding in the Human Brain After Pharmacological Challenge Measured Using PET and PET/MR. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 172.	1.4	6
27	Epistasis of HTR1A and BDNF risk genes alters cortical 5-HT1A receptor binding: PET results link genotype to molecular phenotype in depression. <i>Translational Psychiatry</i> , 2019, 9, 5.	2.4	7
28	Modeling the acute pharmacological response to selective serotonin reuptake inhibitors in human brain using simultaneous PET/MR imaging. <i>European Neuropsychopharmacology</i> , 2019, 29, 711-719.	0.3	11
29	Major Depression and Comorbid Diabetes - Findings from the European Group for the Study of Resistant Depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 94, 109638.	2.5	20
30	Comorbid hypertension in patients with major depressive disorder – Results from a European multicenter study. <i>European Neuropsychopharmacology</i> , 2019, 29, 777-785.	0.3	18
31	Big Data Guided Interventions: Predicting Treatment Response. , 2019, , 53-76.		3
32	Structural changes in amygdala nuclei, hippocampal subfields and cortical thickness following electroconvulsive therapy in treatment-resistant depression: longitudinal analysis. <i>British Journal of Psychiatry</i> , 2019, 214, 159-167.	1.7	71
33	Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples. <i>British Journal of Psychiatry</i> , 2019, 214, 36-41.	1.7	44
34	Parcellation of the Human Cerebral Cortex Based on Molecular Targets in the Serotonin System Quantified by Positron Emission Tomography In vivo. <i>Cerebral Cortex</i> , 2019, 29, 372-382.	1.6	12
35	Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study. <i>Acta Psychiatrica Scandinavica</i> , 2019, 139, 78-88.	2.2	92
36	Psychotic Features in Patients With Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	1.1	28

#	ARTICLE	IF	CITATIONS
37	Task-relevant brain networks identified with simultaneous PET/MR imaging of metabolism and connectivity. <i>Brain Structure and Function</i> , 2018, 223, 1369-1378.	1.2	34
38	Major Depression and the Degree of Suicidality: Results of the European Group for the Study of Resistant Depression (GSRD). <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 539-549.	1.0	54
39	Comorbid thyroid disease in patients with major depressive disorder - results from the European Group for the Study of Resistant Depression (GSRD). <i>European Neuropsychopharmacology</i> , 2018, 28, 752-760.	0.3	47
40	Pleiotropic genes in psychiatry: Calcium channels and the stress-related FKBP5 gene in antidepressant resistance. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 81, 203-210.	2.5	31
41	Clinical factors associated with augmentation treatment with second-generation antipsychotics and lithium in major depression – Results from a European multicenter study. <i>European Neuropsychopharmacology</i> , 2018, 28, 1305-1313.	0.3	15
42	Prediction of Autopsy Verified Neuropathological Change of Alzheimer’s Disease Using Machine Learning and MRI. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 406.	1.7	26
43	Brain monoamine oxidase A in seasonal affective disorder and treatment with bright light therapy. <i>Translational Psychiatry</i> , 2018, 8, 198.	2.4	22
44	Refining Prediction in Treatment-Resistant Depression. <i>Journal of Clinical Psychiatry</i> , 2018, 79, 16m11385.	1.1	76
45	Simple and rapid quantification of serotonin transporter binding using [11C]DASB bolus plus constant infusion. <i>NeuroImage</i> , 2017, 149, 23-32.	2.1	19
46	Association of Protein Distribution and Gene Expression Revealed by PET and Post-Mortem Quantification in the Serotonergic System of the Human Brain. <i>Cerebral Cortex</i> , 2017, 27, 117-130.	1.6	30
47	The impact of comorbid post-traumatic stress disorder in patients with major depressive disorder on clinical features, pharmacological treatment strategies, and treatment outcomes – Results from a cross-sectional European multicenter study. <i>European Neuropsychopharmacology</i> , 2017, 27, 625-632.	0.3	19
48	The influence of the rs6295 gene polymorphism on serotonin-1A receptor distribution investigated with PET in patients with major depression applying machine learning. <i>Translational Psychiatry</i> , 2017, 7, e1150-e1150.	2.4	22
49	Prescribing patterns of psychiatric drugs in major depressive disorder – Findings from a large European multicenter, cross-sectional study. <i>European Psychiatry</i> , 2017, 41, S367-S367.	0.1	0
50	Altered interregional molecular associations of the serotonin transporter in attention deficit/hyperactivity disorder assessed with PET. <i>Human Brain Mapping</i> , 2017, 38, 792-802.	1.9	21
51	Influence of serotonergic gene variants on serotonin transporter binding in ADHD. <i>European Neuropsychopharmacology</i> , 2017, 27, S707.	0.3	0
52	A New Prediction Model for Evaluating Treatment-Resistant Depression. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 215-222.	1.1	73
53	Quantification of Task-Specific Glucose Metabolism with Constant Infusion of ¹⁸ F-FDG. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1933-1940.	2.8	64
54	Subcortical gray matter changes in transgender subjects after long-term cross-sex hormone administration. <i>Psychoneuroendocrinology</i> , 2016, 74, 371-379.	1.3	46

#	ARTICLE	IF	CITATIONS
55	Pharmacological treatment strategies in unipolar depression in European tertiary psychiatric treatment centers – A pharmacoepidemiological cross-sectional multicenter study. <i>European Neuropsychopharmacology</i> , 2016, 26, 1960-1971.	0.3	50
56	Effects of norepinephrine transporter gene variants on <scp>NET</scp> binding in <scp>ADHD</scp> and healthy controls investigated by <scp>PET</scp>. <i>Human Brain Mapping</i> , 2016, 37, 884-895.	1.9	37
57	Socio-demographic and clinical predictors of treatment resistant depression: A prospective European multicenter study. <i>Journal of Affective Disorders</i> , 2016, 189, 224-232.	2.0	73
58	The combined effect of genetic polymorphisms and clinical parameters on treatment outcome in treatment-resistant depression. <i>European Neuropsychopharmacology</i> , 2015, 25, 441-453.	0.3	77
59	Sex-specific differences in diabetes prevention: a systematic review and meta-analysis. <i>Diabetologia</i> , 2015, 58, 242-254.	2.9	42
60	Sex-specific-differences in cardiometabolic risk in type 1 diabetes: a cross-sectional study. <i>Cardiovascular Diabetology</i> , 2013, 12, 78.	2.7	38
61	Colour doppler imaging of partial subclavian steal syndrome. <i>Neuroradiology</i> , 1993, 35, 293-295.	1.1	8